Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium augmentation in escitalopram-treated major depression
DRKS00004551Phase 3Recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of lithium carbonate in major depressive disorder (MDD) and recurrent depressive disorder (RDD), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Antidepressive efficacy of lithium augmentation, Safety of lithium augmentation and 2 more. Started Jan 2013; status: recruiting.
02
Drugs
lithium carbonate
03
Conditions
major depressive disorder (MDD)recurrent depressive disorder (RDD)
Beyond the preview
Go deeper on DRKS00004551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00004551.